Source: Google NewsPublished on 2023-05-25
Related Articles:
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- HanAll Biopharma and Daewoong Pharmaceutical Enter into Co ... - PR Newswire May 25, 2023 HanAll Biopharma and Daewoong Pharmaceutical Enter into Co ... PR Newswire
- HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease May 25, 2023 HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders Phase 1 clinical trial is...
- HanAll Biopharma, Daewoong Pharmaceutical to co-develop Parkinson's drug with NurrOn - KBR May 25, 2023 HanAll Biopharma, Daewoong Pharmaceutical to co-develop Parkinson's drug with NurrOn KBR
- HanAll Biopharma, Daewoong sign deal for Parkinson's therapy - Pharmaceutical Technology May 26, 2023 HanAll Biopharma, Daewoong sign deal for Parkinson's therapy Pharmaceutical Technology
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Daewoong, Hanall invest in NurrOn Pharmaceuticals for collaboration in US - Korea Biomedical Review July 29, 2021 Daewoong, Hanall invest in NurrOn Pharmaceuticals for collaboration in US Korea Biomedical Review
- HanAll, Daewoong Developing Parkinson's Disease Treatment with ... - BusinessKorea May 26, 2023 HanAll, Daewoong Developing Parkinson's Disease Treatment with ... BusinessKorea
- Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
- Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
- XWPharma Names Michael M. Morrissey, PhD to Board of DirectorsAppointment Adds Senior Biopharma Operational Expertise to Board Oversight as Company Advances its Pipeline of Novel CNS Therapeutics in Research and Clinical Development - BioSpace December 16, 2020 XWPharma Names Michael M. Morrissey, PhD to Board of DirectorsAppointment Adds Senior Biopharma Operational Expertise to Board Oversight as Company Advances its Pipeline of Novel CNS Therapeutics in Research and Clinical Development BioSpace
- Biopharma Money on the Move: December 16-22 - BioSpace December 23, 2020 Biopharma Money on the Move: December 16-22 BioSpace
- Biopharma is Tackling Misfolding Proteins in Parkinson's Disease - BioSpace December 2, 2021 Biopharma is Tackling Misfolding Proteins in Parkinson's Disease BioSpace
- Better Together: Biopharma Companies Team Up Against Complex Diseases - BioSpace April 19, 2022 Better Together: Biopharma Companies Team Up Against Complex Diseases BioSpace
- 4D Pharma to trial LBPs in patients with Parkinson's disease: 'We are continuing to expand clinical pathways for the microbiome field' - BioPharma-Reporter.com February 22, 2022 4D Pharma to trial LBPs in patients with Parkinson's disease: 'We are continuing to expand clinical pathways for the microbiome field' BioPharma-Reporter.com4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson's Disease BioSpace4D pharma receives US regulatory green light for phase I trial of Parkinson"s disease candidates Proactive Investors USA4D Pharma Shares Rise as…
- Three Biopharma Companies to Settle into New Breakthrough Properties Home - BioSpace March 10, 2022 Three Biopharma Companies to Settle into New Breakthrough Properties Home BioSpace
- Wet Lab Space, Entrepreneur Support, Cement Chicago as Serious Biopharma Hotbed - BioSpace September 19, 2022 Wet Lab Space, Entrepreneur Support, Cement Chicago as Serious Biopharma Hotbed BioSpace
- UCB at ANN looks A-OK April 26, 2021 # # # # Alpha synuclein is one of the most common proteins in our brains and it has long been associated with Parkinson’s. The protein appears to clump together forming dense clusters ( or “aggregates“) in the Parkinsonian brain, and this may be related to the progressive neurodegeneration. Researchers have been desperately seeking small molecules that will break up…
- Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes - BioSpace September 2, 2021 Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes BioSpace
- FDA Clears AskBio's AAV Gene Therapy for Muscular Dystrophy to Enter Phase I/II - BioSpace May 25, 2021 FDA Clears AskBio's AAV Gene Therapy for Muscular Dystrophy to Enter Phase I/II BioSpace